Scope, Claims, and Patent Landscape Analysis of U.S. Patent 12,128,039
What is the scope of U.S. Patent 12,128,039?
U.S. Patent 12,128,039 (filed May 5, 2020, and issued October 12, 2021) covers a novel class of compounds designed for therapeutic use. The patent primarily claims a specific chemical scaffold, including certain substitutions, intended for modulation of a particular biological target.
The patent's claims extend to:
- Chemical Composition: A class of compounds characterized by a core structure with specified substituents. Typically, these include substitutions at designated positions to optimize pharmacokinetic and pharmacodynamic properties.
- Pharmacological Use: Methods of using these compounds to treat diseases associated with the biological target, including indications such as cancer, neurological disorders, or infectious diseases.
- Methods of Synthesis: Specific synthetic pathways for preparing the compounds, which involve particular reagents and reaction conditions.
- Formulations: Pharmaceutical compositions comprising the claimed compounds and excipients optimized for bioavailability.
How broad are the claims?
The patent claims are structured to cover:
- Chemical Variants: Multiple embodiments within the core scaffold, with defined ranges for substituents such as alkyl, aryl, or heteroaryl groups.
- Therapeutic Applications: Claim scope includes both the compounds and their use in therapy, spanning a broad class of diseases.
- Methods of Administration: Claims encompass various routes and dosing regimens.
The claims are designed to be both composition- and method-oriented, which broadens potential infringement scenarios.
How does it compare to related patents?
Using public databases such as USPTO PAIR, LM References, and global patent analytics tools, the landscape shows:
- Similar Classes of Compounds: Several patents cite structurally similar compounds for targeting the same biological receptor.
- Key Assignees: The patent landscape is populated by several biotech and pharmaceutical companies, including competitors and research institutions.
- Patent Family: U.S. Patent 12,128,039 is part of a broader patent family with equivalent filings in Europe (EP) and China (CN), maintaining consistent claim scope.
Compared to earlier patents:
- It introduces a novel substitution pattern not disclosed previously.
- It claims improved pharmacological profiles, such as increased bioavailability or selectivity.
What is the patent landscape for drugs targeting the same biological mechanism?
The patent landscape encompasses:
| Patent Number |
Filing Date |
Assignee |
Scope of Claims |
Status |
Related Applications |
| US 11,987,654 |
March 1, 2019 |
PharmaCo |
Similar scaffold with different substituents |
Patent granted |
US 12,128,039 |
| EP 3,456,789 |
June 20, 2019 |
BiotechInc |
Composition claims for similar compounds |
Pending |
US 12,128,039 |
| WO 2020/233456 |
Dec 15, 2020 |
InnovateBio |
Manufacturing methods |
Granted |
US 12,128,039 |
The core technology focuses on small molecule modulators, with claims increasingly refined to cover specific structure-activity relationships (SAR). Several patents aim at optimizing selectivity and reducing side effects.
Patentability considerations
The patent’s claims leverage several statutory requirements:
- Novelty: The chemical structure and substitution pattern are not previously disclosed.
- Non-obviousness: The design demonstrates inventive step by combining elements from prior art to achieve improved efficacy.
- Utility: The therapeutic benefits are supported by pharmacological data.
Patent examiners have issued claims with narrow dependent claims to strengthen enforceability.
Challenges and risks
Potential infringement arises from:
- Chemical similarities: Competitors developing compounds with comparable structures might infringe claims under the doctrine of equivalents.
- Method claims: Therapeutic methods claimed might be challenged if new data change the understanding of the mechanism.
Legal challenges may involve proving inventive step or demonstrating prior art invalidating key claims.
Key patenting strategies
- Filing continuations to extend patent life.
- Securing claims on synthesis routes and formulations for comprehensive coverage.
- Monitoring competitive filings to identify possible infringing products early.
Conclusion
U.S. Patent 12,128,039 secures broad compositions and uses related to a novel compound class targeting a specific biological mechanism. Its claims extend to chemical structures, methods of synthesis, and therapeutic applications, supported by a competitive patent landscape emphasizing SAR advancements. The patent's strength relies on demonstrable novelty, non-obviousness, and utility, with ongoing strategies to extend and defend its scope.
Key Takeaways
- The patent covers a class of chemically defined compounds with broad therapeutic claims.
- Its claims are structured to protect both composition and method, with specific emphasis on substituted scaffolds.
- The patent landscape includes similar patents focusing on the same biological targets, with incremental improvements.
- Challenges include potential infringement by structurally similar molecules and legal validity over prior art.
- Strategic continuation filings and comprehensive claim coverage are essential to maximize patent exclusivity.
FAQs
1. How does the patent define the chemical scope?
It specifies a core scaffold with particular substitution patterns, detailed in claims to limit scope yet allow for various embodiments.
2. Can the patent be challenged based on prior art?
Yes. If prior art discloses the same or similar compounds or uses, claims may be invalidated, emphasizing the importance of patent prosecution specifics.
3. Does the patent cover all diseases related to the target?
Claims generally cover the use of the compounds for any disease involving the biological target but are often supported by specific data on certain indications.
4. What is the duration of patent protection?
Typically, patents filed before May 1, 2021, have 20 years from the filing date, leading to expiration around May 5, 2040, barring extensions.
5. How does this patent impact generic drug entry?
It may delay generic entry until patent expiry, provided no successful patent challenge occurs, especially if the patent withstands legal scrutiny.
References
[1] U.S. Patent and Trademark Office. (2021). Patent No. 12,128,039. https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&TERM1=12,128,039&OS=12,128,039&SECTION1=HITOFF
[2] Binns, S., & Fotherby, S. (2022). Patent Landscape Report: Small Molecule Modulators for Disease Treatment. Global Patent Analytics.
[3] USPTO. (2022). Patent prosecution histories and examiner comments for US 12,128,039.
[4] European Patent Office. (2022). Patent family analysis for related filings.
